Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Zioptan

(Tafluprost)

Phase 3Small molecule

Zioptan is one of 45 small molecule programs targeting Glaucoma. It is currently in Phase 3.

2

Indications

5

Total Trials

0

Active Trials

44

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

2

Patents

Pipeline

Status by Indication[3][1]

Indication

GlaucomaActive, not recruiting

Ocular HypertensionActive, not recruiting

GlaucomaPhase 3

Active, not recruiting

Ocular HypertensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Alphagan

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Comparator: Pbo

Ocupress

Zioptan

LUMIGAN

Krytantek

Preservative-Free Tafluprost

Reference - LUMIGAN

AAmneal Pharmaceuticals, LLC

Combigan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glaucoma3 trials

Switching From Preserved to Preserved-free Treatments for Glaucoma.

Unknown status·PPaolo Fogagnolo·Phase 3·NCT01433900·40 enrolled

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

Completed·SSanten Oy·Phase 3·NCT01087671·185 enrolled

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

Completed·SSanten Oy·Phase 3·NCT00596791·150 enrolled

Efficacy1 trial

24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

Completed·—·Phase 4·NCT02802137·43 enrolled

Ocular Hypertension1 trial

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

Completed·SSanten Pharmaceutical (Taiwan) Co., LTD·N/A·NCT04737928·1 enrolled

Regulatory

FDA Approval Timeline[4]

Feb 10, 2012

ZIOPTAN

NDA NDA202514

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Tafluprost. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tafluprost compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tafluprost. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA202514). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Zioptan. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Meitheal company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMeitheal

Patent Landscape[5]

Patent Cliff

May 28, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10864159May 28, 2029

9999593May 28, 2029

Related News